

GLAXOSMITHKLINE PLC  
Form 6-K  
October 16, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 16 October 2018

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley  
Chief Executive Officer
- b) Position/status

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018, on shares held through the Company's Share Reward Plan.

- c) Price(s) and volume(s)
- | Price(s)                 | Volume(s) |
|--------------------------|-----------|
| £14.7623                 | 18        |
| n/a (single transaction) |           |

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2018-10-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr R G Connor
- b) Position/status President, Global Vaccines

c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- |                          |   |  |          |           |          |    |                          |  |
|--------------------------|---|--|----------|-----------|----------|----|--------------------------|--|
| a)                       | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882   |          |           |          |    |                          |  |
| b)                       | Nature of the transaction               | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018, on shares held through the Company's Share Reward Plan.                                   |          |           |          |    |                          |  |
| c)                       | Price(s) and volume(s)                  | <table border="0"> <tr> <td style="padding-right: 20px;">Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£14.7623</td> <td>65</td> </tr> <tr> <td colspan="2">n/a (single transaction)</td> </tr> </table> | Price(s) | Volume(s) | £14.7623 | 65 | n/a (single transaction) |  |
| Price(s)                 | Volume(s)                               |  |          |           |          |    |                          |  |
| £14.7623                 | 65                                      |  |          |           |          |    |                          |  |
| n/a (single transaction) |   |  |          |           |          |    |                          |  |

d) Aggregated information  
Aggregated volume Price

- |    |                          |                              |
|----|--------------------------|------------------------------|
| e) | Date of the transaction  | 2018-10-11                   |
| f) | Place of the transaction | London Stock Exchange (XLON) |

1. Details of PDMR/person closely associated with them ('PCA')

- |    |                                    |                         |
|----|------------------------------------|-------------------------|
| a) | Name                               | Mr S Dingemans          |
| b) | Position/status                    | Chief Financial Officer |
| c) | Initial notification/<br>amendment | Initial notification    |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- |    |      |                      |
|----|------|----------------------|
| a) | Name | GlaxoSmithKline plc  |
| b) | LEI  | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- |    |   |   |
|----|---|---|
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')<br>ISIN: GB0009252882  |
| b) | Nature of the transaction               | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018, on shares held |

through the Company's Share  
Reward Plan.

c) Price(s) and volume(s)                      Price(s)              Volume(s)  
£14.7623              24  
n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction                      2018-10-11  
f) Place of the transaction                      London Stock Exchange  
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name    Mr N Hirons  
b) Position/status                                SVP, Global Ethics &  
Compliance

c) Initial notification/  
amendment                                        Initial notification

2. Details of the issuer, emission allowance market participant, auction  
platform, auctioneer or auction monitor

a) Name    GlaxoSmithKline plc  
b) LEI     5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type  
of instrument; (ii) each type of transaction; (iii) each date; and (iv)  
each place where transaction(s) has been conducted

a) Description of the financial instrument    Ordinary shares of 25 pence  
each ('Ordinary Shares')  
ISIN: GB0009252882

b) Nature of the transaction                    Acquisition of Ordinary  
Shares following the  
re-investment of dividends  
paid to shareholders on 11  
October 2018, on shares held  
through the Company's Share  
Reward Plan.

c) Price(s) and volume(s)                      Price(s)              Volume(s)  
£14.7623              11

d) Aggregated information                      n/a (single transaction)

Aggregated volume Price

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

e) Date of the transaction 2018-10-11  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr L Miels  
 President, Global  
 b) Position/status Pharmaceuticals

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence  
 each ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction Acquisition of Ordinary  
 Shares following the  
 re-investment of dividends  
 paid to shareholders on 11  
 October 2018, on shares held  
 through the Company's Share  
 Reward Plan.

c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £14.7623 2  
 n/a (single transaction)

d) Aggregated information  
 Aggregated volume Price

e) Date of the transaction 2018-10-11  
 f) Place of the transaction London Stock Exchange  
 (XLON)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr D S Redfern
  - b) Position/status Chief Strategy Officer
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
  - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
  - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018, on shares held through the Company's Share Reward Plan.
  - c) Price(s) and volume(s)
 

Price(s)	Volume(s)
£14.7623	73
n/a (single transaction)	
  - d) Aggregated information  
Aggregated volume Price
  - e) Date of the transaction 2018-10-11
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr R Simard
  - b) Position/status President, Pharmaceutical Supply Chain
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018, on shares held through the Company's Share Reward Plan.
- c) Price(s) and volume(s)  
Price(s) Volume(s)  
£14.7623 18  
n/a (single transaction)

d) Aggregated information  
Aggregated volume Price

- e) Date of the transaction 2018-10-11
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms C Thomas
- b) Position/status SVP, Human Resources
- c) Initial notification/  
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11

October 2018, on shares held through the Company's Share Reward Plan.

c) Price(s) and volume(s)  
 Price(s)      Volume(s)  
 £14.7623      73  
 n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction      2018-10-11  
 f) Place of the transaction      London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name      Mr P C Thomson  
 b) Position/status      President, Global Affairs

c) Initial notification/ amendment      Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name      GlaxoSmithKline plc  
 b) LEI      5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument      Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

b) Nature of the transaction      Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018, on shares held through the Company's Share Reward Plan.

c) Price(s) and volume(s)  
 Price(s)      Volume(s)  
 £14.7623      41  
 d) Aggregated information      n/a (single transaction)

Aggregated volume Price



- e) Date of the transaction 2018-10-11  
 f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mrs V A Whyte  
 b) Position/status Company Secretary  
 c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')  
 ISIN: GB0009252882

- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 October 2018, on shares held through the Company's Share Reward Plan.

- c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £14.7623 53  
 n/a (single transaction)

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2018-10-11  
 f) Place of the transaction London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: October 16, 2018

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc